Glycated hemoglobin

There are 483 papers on glycated hemoglobin in aging research: 95 trials and 273 observational studies in people, 15 in animals, 85 reviews.

Biomarker

483 papers study it816 more mention it187 findings

MeSH

117 new papers in 30 daysSee all 1,299 papers on glycated hemoglobin

At a glance

Higher glycated hemoglobin is linked with mortality in older patients with femoral neck fractures and, in a preprint, with frailty in community-dwelling Chinese adults. Human studies also link it with cognition, handgrip strength and gait speed; human trials report lower levels with exercise and several diabetes drugs.

187 findings in 158 papers from 1984 to 2026, 30 of them since June 2026

“Baseline and average HbA1c levels over time of <7%, as compared with ≥8%, were associated with less increase in FI scores over 8 years (both P ≤ 0.002).”
An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) TrialDiabetes care2022doi:10.2337/dc22-1728
  • Human trial95
  • Humans273
  • Animals15
  • In silico6

Interventions

64

Tirzepatide

downin humans16upin humans1

17 studies
  1. Tirzepatide decreases glycated hemoglobin in humans (severe MASH and diabetes; switched from liraglutide).

    “Over 6 months of administration of tirzepatide, the patient's glycated hemoglobin and elevated liver enzyme levels improved.”

    Human trialsevere MASH and diabetes; switched from liraglutide6 monthsmalesn = 1

    Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide

    Frontiers in endocrinology

  2. Tirzepatide decreases glycated hemoglobin in humans (vs dulaglutide; post hoc split by baseline C-peptide (cutoff 1.86 μg/l)) (C-peptide <1.86 μg/l: -2.31% to -2.75% vs -1.45%; ≥1.86 μg/l: -2.43% to -2.89% vs -1.12%).

    “the tirzepatide groups showed significant improvement in glycated hemoglobin at week 52 compared with the dulaglutide group”

    Human trialvs dulaglutide; post hoc split by baseline C-peptide (cutoff 1.86 μg/l)5, 10, 15 mg once weekly52 weeksn = 636

    Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis

    Diabetes therapy : research, treatment and education of diabetes and related disorders

  3. Tirzepatide decreases glycated hemoglobin in humans (compared with placebo, in T2DM patients with overweight/obesity) (-1.64 (-1.94, -1.35) vs placebo).

    “Tirzepatide showed superior effects in lowering blood glucose (Compared with placebo, increased glycated hemoglobin: -1.64 (-1.94, -1.35)”

    Human trialcompared with placebo, in T2DM patients with overweight/obesity

    Comparison of the effectiveness and safety of GLP-1 receptor agonists for type 2 diabetes mellitus patients with overweight/obesity: A systematic review and network meta-analysis

    Diabetes research and clinical practice

  4. Tirzepatide decreases glycated hemoglobin in humans (adjusted indirect comparison versus semaglutide 0.5 mg).

    “All tirzepatide doses showed statistically significantly greater reductions in glycated haemoglobin, body weight and body mass index from baseline to week 40”

    Human trialadjusted indirect comparison versus semaglutide 0.5 mg5, 10 and 15 mgweek 40

    Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison

    Diabetes research and clinical practice

  5. Tirzepatide decreases glycated hemoglobin in humans (ranked in the top three by network meta-analysis).

    “Tirzepatide 15 mg ranked in the top three across weight-related parameters, glycemic profile (glycated hemoglobin)”

    Human trialranked in the top three by network meta-analysis15 mg

    Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis

    Obesity (Silver Spring, Md.)

  6. Tirzepatide decreases glycated hemoglobin in humans (compared with basal insulin and selective GLP1-RA in network meta-analysis) (SCURA probability 93.5%).

    “15 mg of tirzepatide was dominant on reducing glycated hemoglobin (SCURA probability: 93.5%)”

    Human trialcompared with basal insulin and selective GLP1-RA in network meta-analysis15 mg

    Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis

    Frontiers in pharmacology

  7. Tirzepatide decreases glycated hemoglobin in humans (compared with semaglutide 1 mg; largest difference at 15 mg) (-0.45 percentage points for 15 mg versus semaglutide (95% CI -0.57 to -0.32); -0.15 and -0.39 for 5 and 10 mg).

    “Tirzepatide at all doses was noninferior and superior to semaglutide.”

    Human trialcompared with semaglutide 1 mg; largest difference at 15 mg15 mg40 weeksn = 1,879

    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

    The New England journal of medicine

  8. Tirzepatide is linked with lower glycated hemoglobin in humans (compared with matched controls) (-0.50 ± 0.07% vs -0.24 ± 0.09% in controls; P = 0.017).

    “The HbA1c decreased more in patients using tirzepatide than controls (-0.50 ± 0.07% and -0.24 ± 0.09%, respectively, P = 0.017).”

    Humanscompared with matched controls21 monthsn = 84

    Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months

    Diabetes technology & therapeutics

  9. Tirzepatide is linked with lower glycated hemoglobin in humans (compared with GLP-1 RA in adults with type 2 diabetes) (treatment difference -0.34 percentage points (95% CI -0.44 to -0.24)).

    “Treatment with tirzepatide was associated with greater decreases in glycated hemoglobin (treatment difference, -0.34 percentage points; 95% CI, -0.44 to -0.24 percentage points)”

    Humanscompared with GLP-1 RA in adults with type 2 diabetes

    Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes

    JAMA network open

  10. Tirzepatide improves glycated hemoglobin in humans (compared with semaglutide).

    “Tirzepatide was also associated with greater improvements in blood pressure and glycated haemoglobin”

    Reviewcompared with semaglutide

    Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review

    Cureus

All 17

More on Tirzepatide

Acarbose

downin humans6no changein humans1downin rats1

8 studies
  1. Acarbose decreases glycated hemoglobin in humans (-0.79% to -1.32% across baseline glucagon tertiles).

    “Significant reductions in HbA1c were observed in both acarbose and metformin groups at 24 and 48 weeks”

    Human trial300 mg/day24 and 48 weeks

    Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study

    Diabetes research and clinical practice

  2. Acarbose decreases glycated hemoglobin in humans (compared with metformin; similar reduction in all beta-cell function groups) (similar to metformin; no values given).

    “both acarbose and metformin could decrease glycated hemoglobin to similar levels after 48 weeks treatment in all groups”

    Human trialcompared with metformin; similar reduction in all beta-cell function groups300 mg/d48 weeks

    Comparison of therapeutic effects of acarbose and metformin under different β-cell function status in Chinese patients with type 2 diabetes

    Endocrine journal

  3. Acarbose decreases glycated hemoglobin in humans (-1.8% points (HbA1c); -2.4% points (HbA1)).

    “Over the 5 years, HbA(1) and glycated haemoglobin (HbA(1c)) decreased by 2.4 and 1.8% points, respectively”

    Human trial5 years

    Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study

    Diabetes research and clinical practice

  4. Acarbose decreases glycated hemoglobin in patients with inadequate control on diet and sulphonylureas (from 8.36 to 7.71%).

    “glycosilated hemoglobin decreased from 8.36 +/- 1.33 to 7.71+ 1.7% (p < 0.001)”

    Human trialin patients with inadequate control on diet and sulphonylureas150 mg/day for 4 weeks, then 300 mg/day for 3 monthsn = 64

    Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study

    Revista medica de Chile

  5. Acarbose showed no clear effect on glycated hemoglobin in humans (versus placebo).

    “fasting glucose and % HbAl concentrations were not different from those observed during placebo therapy”

    Human trialversus placebo300 mg/dayone monthn = 18

    Treatment of poorly controlled non-insulin-dependent diabetic patients with Acarbose

    Australian and New Zealand journal of medicine

  6. Acarbose decreases glycated hemoglobin in humans (mainly via its effects on postprandial hyperglycemia).

    “Agents such as acarbose, which has been shown to reduce 24-h glycemia and glycated hemoglobin”

    Reviewmainly via its effects on postprandial hyperglycemia

    Acarbose revisited for efficacy, safety and cardiovascular benefits: a key role for controlling glycemic variability

    Expert review of endocrinology & metabolism

  7. Acarbose decreases glycated hemoglobin in humans (as monotherapy and as add-on to other antidiabetic drug treatment).

    “Treatment with acarbose significantly reduced glycated hemoglobin levels when given as monotherapy and as an add-on to other antidiabetic drug treatment (P < 0.0001).”

    Reviewas monotherapy and as add-on to other antidiabetic drug treatment

    Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review

    Clinical therapeutics

  8. Acarbose decreases glycated hemoglobin in rats (non-diabetic rats compared with untreated controls).

    “acarbose-treated non-diabetic control rats who demonstrated decreased glycated hemoglobin levels compared to non-treated control rats.”

    Animalsnon-diabetic rats compared with untreated controls

    The effect of acarbose on diabetes- and age-related basement membrane thickening in retinal capillaries of the BB/W-rat

    Diabetes research and clinical practice

More on Acarbose

SGLT2 inhibitors

downin humans4

4 studies
  1. SGLT2 inhibitors are linked with lower glycated hemoglobin in humans (patients with type 2 diabetes starting SGLT2i after age 70) (7.8 ± 1.1 to 7.1 ± 0.8%, p < 0.001).

    “A statistically significant reduction of glycated hemoglobin (baseline vs 12 months: 7.8 ± 1.1 vs 7.1 ± 0.8%, p < 0.001)”

    Humanspatients with type 2 diabetes starting SGLT2i after age 7012 months

    SGLT2-inhibitors are effective and safe in the elderly: The SOLD study

    Pharmacological research

  2. SGLT2 inhibitors decrease glycated hemoglobin in patients with diabetic CKD (MD = -0.40%, 95% CI: -0.44 to -0.36).

    “SGLT2 inhibitors significantly reduced glycated hemoglobin levels (MD = -0.40%, 95% CI: -0.44 to -0.36)”

    Reviewin patients with diabetic CKD

    Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis

    Medicine

  3. SGLT2 inhibitors decrease glycated hemoglobin in humans (type 1 diabetes; add-on to insulin pump therapy) (MD -0.30%, 95% CI -0.41 to -0.20).

    “Glycated hemoglobin decreased significantly (MD -0.30%, [-0.41 to -0.20]);”

    Reviewtype 1 diabetes; add-on to insulin pump therapy

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors as Add-On Therapy to Insulin Pumps for Type 1 Diabetes: A Systematic Review and Meta-Analysis

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

  4. SGLT2 inhibitors decrease glycated hemoglobin in humans.

    “Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors are newer antihyperglycemic agents that effectively lower glycated hemoglobin levels”

    Review

    Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies

    The Journal of family practice

More on SGLT2 inhibitors

GLP-1 receptor agonists

downin humans2downin reviews1

3 studies
  1. GLP-1 receptor agonists are linked with lower glycated hemoglobin in humans (−1.6 percentage points (SD 1.3), from baseline 8.3%).

    “By the end of the study, patients reduced their glycated hemoglobin by 1.6% (SD = 1.3) from a baseline of 8.3%”

    HumansType 2 diabetes; exit-interview sample from ACHIEVE-3, without a between-treatment comparisonOralBoth; 28 femalesn = 60

    Qualitative Exit Interviews to Characterize the Positive Treatment Experiences of Patients in the Phase III Trial of Orforglipron Versus Oral Semaglutide for the Treatment of Type 2 Diabetes

    The patient

  2. GLP-1 receptor agonists decrease glycated hemoglobin.

    “Large clinical trials have supported GLP-1 RAs as an excellent option for reducing glycated hemoglobin and body weight, as well as for reducing major renal and cardiovascular adverse effects”

    Review

    Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults

    Advances in therapy

  3. GLP-1 receptor agonists decrease glycated hemoglobin in humans.

    “Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors are newer antihyperglycemic agents that effectively lower glycated hemoglobin levels”

    Review

    Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies

    The Journal of family practice

More on GLP-1 receptor agonists

Semaglutide

downin humans3

3 studies
  1. Semaglutide is linked with lower glycated hemoglobin in humans (caution in interpreting magnitude and speed).

    “Following the high dose of semaglutide, glycated hemoglobin decreased”

    Humanscaution in interpreting magnitude and speed0.5mg/weekmalesn = 1

    Simultaneous bilateral NAION following initiation of high-dose semaglutide: a case report

    Archivos de la Sociedad Espanola de Oftalmologia

  2. Semaglutide is linked with lower glycated hemoglobin in humans (as an add-on therapy to insulin in LADA patients).

    “semaglutide users showed statistically significant reduction in glycated hemoglobin, body mass index, and insulin total daily dose.”

    Humansas an add-on therapy to insulin in LADA patients6 monthsn = 68

    The use of semaglutide as an add-on therapy in patients with latent autoimmune diabetes in adults

    The Journal of clinical endocrinology and metabolism

  3. Semaglutide decreases glycated hemoglobin in humans (versus placebo in PIONEER 5) (ETD -0.8%; 95% CI -1.0, -0.6).

    “oral semaglutide was superior to placebo in decreasing glycated hemoglobin over 26 weeks (estimated treatment difference [ETD]: -0.8%; 95% CI: -1.0, -0.6; p < 0.0001)”

    Reviewversus placebo in PIONEER 5oral tablet formulation26 weeks

    Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients

    Postgraduate medicine

More on Semaglutide

Resistance training

downin humans2no changein humans1

3 studies
  1. Resistance training decreases glycated hemoglobin in humans (CKD undergoing maintenance hemodialysis).

    “Glycated hemoglobin, inflammatory cytokines, and triglycerides decreased in RT and RT-CS groups as compared with pre-intervention and CG”

    Human trialCKD undergoing maintenance hemodialysis24 weeksn = 78

    Impact of cluster set resistance training on strength, functional capacity, metabolic and inflammatory state in older hemodialysis subjects: A randomized controlled clinical trial

    Experimental gerontology

  2. Resistance training showed no clear effect on glycated hemoglobin in humans (between-group comparison with active control).

    “No significant differences were found for blood lipid profile and glycated hemoglobin for both groups after the intervention period.”

    Human trialbetween-group comparison with active control12 weeks

    Effects of short-term resistance training on endothelial function and inflammation markers in elderly patients with type 2 diabetes: A randomized controlled trial

    Experimental gerontology

  3. Resistance training decreases glycated hemoglobin in humans (mean difference -0.66 %, 95 % CI -1.01 to -0.33, p = 0.0002).

    “glycated hemoglobin (mean difference -0.66 %, 95 % CI -1.01 to -0.33, p = 0.0002)”

    Reviewin women with overweight or obesity who are middle-aged or older and have type 2 diabetes mellitusfemalesn = 315

    The effects of resistance training on glycemic control, cardiometabolic health, and body composition in middle-aged and older women with type 2 diabetes and overweight or obesity: A systematic review and meta-analysis

    Maturitas

More on Resistance training

Exercise

downin humans2

2 studies
  1. Exercise decreases glycated hemoglobin in humans (post-bariatric surgery, at 4 months) (-0.3%; 95% CI, -0.5 to -0.1).

    “and glycated hemoglobin (- 0.3%; 95% CI, - 0.5 to - 0.1; p = 0.018) at 4 months.”

    Human trialpost-bariatric surgery, at 4 monthsindividually supervised concurrent exercise trainingthree 60-min sessions/week16 weeksn = 80

    Effects of supervised exercise immediately after bariatric surgery: results from the EFIBAR randomized trial

    Obesity surgery

  2. Exercise decreases glycated hemoglobin in humans (Hedges’ g = −0.52).

    “improved glucose metabolism, reducing FPG (Hedges’ g = −0.42, p < 0.001), HbA1c (Hedges’ g = −0.52, p < 0.001), and HOMA-IR (Hedges’ g = −0.48, p < 0.001”

    Human trial6 to 52 weeksn = 2,578

    Effects of exercise intervention on glucose and lipid metabolism in patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease: a three-level meta-analysis

    Frontiers in nutrition

  3. Exercise decreases glycated hemoglobin in patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease (Hedges' g = -0.52, p < 0.001).

    “exercise reduced BMI (Hedges' g = -0.36, p < 0.001), FPG (Hedges' g = -0.42, p < 0.001), HbA1c (Hedges' g = -0.52, p < 0.001)”

    Human trialin patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease

    Effects of exercise intervention on glucose and lipid metabolism in patients with type 2 diabetes mellitus complicated by non-alcoholic fatty liver disease: a three-level meta-analysis

    Frontiers in nutrition

More on Exercise

Spermidine

downin humans1downin rats1

2 studies
  1. Spermidine decreases glycated hemoglobin in humans (cluster 3, highest baseline and increased 1-year spermidine intake) (-0.14 [-0.18 to -0.10]%).

    “glycated hemoglobin levels (- 0.14 [- 0.18 to - 0.10]%, p-int < 0.01)”

    Human trialcluster 3, highest baseline and increased 1-year spermidine intake1 year

    Rising spermidine intake linked to better liver scores

    European journal of nutrition

  2. Spermidine decreases glycated hemoglobin in alloxan-induced diabetic rats.

    “The L-arginine and spermidine injection tended to normalize the glycemia from 24 hours, similarly, hyperlipidemia, TBARS, and HbA(1C).”

    Animalsin alloxan-induced diabetic rats10 microM

    Inhibition by L-arginine and spermidine of hemoglobin glycation and lipid peroxidation in rats with induced diabetes

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Spermidine

Yoga

no changein humans1downin humans1

2 studies
  1. Yoga showed no clear effect on glycated hemoglobin in humans (type 2 diabetes mellitus) (from 6.74% to 6.47%, p=0.10).

    “HbA1c levels decreased from 6.74% to 6.47%, however, this change did not reach statistical significance (p=0.10).”

    Human trialtype 2 diabetes mellitus12-weekn = 12

    Finding Balance: Yoga as an Adjunct Therapy in Adults with Type 2 Diabetes Mellitus, a Prospective Study

    ADA Scientific Sessions 2026 abstract

  2. Yoga decreases glycated hemoglobin in humans (type 2 diabetes and non-alcoholic fatty liver disease).

    “The cyclic yoga group showed significant reductions in fasting blood glucose, glycated hemoglobin, insulin resistance, triglycerides, low-density lipoprotein cholesterol”

    Human trialtype 2 diabetes and non-alcoholic fatty liver diseaseeight-weekfemalesn = 40

    Effects of cyclic yoga on selected metabolic and hepatic parameters in diabetic women with fatty liver diseases: A clinical trial

    Journal of clinical & translational endocrinology

More on Yoga

Retatrutide

downin humans2−2.2%

2 studies
  1. Retatrutide decreases glycated hemoglobin in subjects with type 2 diabetes mellitus (up to 2.16%).

    “In subjects with type 2 diabetes mellitus (T2DM), decreased glycated hemoglobin (HbA1c) by up to 2.16%”

    Reviewin subjects with type 2 diabetes mellitus

    Retatrutide in type 2 diabetes mellitus and obesity: an overview

    Expert review of clinical pharmacology

  2. Retatrutide decreases glycated hemoglobin in individuals with type 2 diabetes, phase-2 trials.

    “Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).”

    Reviewin individuals with type 2 diabetes, phase-2 trials

    Retatrutide: a triple incretin receptor agonist for obesity management

    Expert opinion on investigational drugs

More on Retatrutide

Liraglutide

downin humans2

2 studies
  1. Liraglutide decreases glycated hemoglobin in humans (MD -0.19%; 95% CI -0.25 to -0.13).

    “and HbA1c (MD -0.19%; 95% CI -0.25 to -0.13)”

    Human trial

    Comparative effectiveness of continuous positive airway pressure and glucagon-like peptide-1 receptor agonists in obstructive sleep apnea: A network meta-analysis of randomised trials

    Diabetes, obesity & metabolism

  2. Liraglutide decreases glycated hemoglobin in humans (−1.1% (95% CI −1.3 to −0.9)).

    “The estimated treatment differences of all three liraglutide groups compared with the placebo group and the resulting 95% CIs demonstrated that liraglutide-treated subjects had superior glycemic control compared with those in the placebo group”

    Human trial26 weeksn = 1,091

    Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

    Diabetes care

More on Liraglutide

High-fiber diet

downin humans1

1 study
  1. High-fiber diet decreases glycated hemoglobin (6.32, 95% CI 6.11–6.53, vs. 6.74, 95% CI 6.39–7.09).

    “At Day 84, the baseline-adjusted means were significantly lower in the W group than in the U group for both HbA1c (6.32, 95% CI 6.11–6.53, vs. 6.74, 95% CI 6.39–7.09; p = 0.042) and BMI (28.42 kg/m, 95% CI 28.07–28.78, vs. 30.22 kg/m, 95% CI 29.61–30.83; p < 0.001) ( Figures 1A, F; Supplementary Table S4”

    Human trial84-day interventionn = 48

    High-fiber diet altered gut microbiota, improved glycemic control, and reduced body weight in newly diagnosed type 2 diabetes and obesity

    Frontiers in microbiology

  2. High-fiber diet decreases glycated hemoglobin in humans.

    “At Day 84, the high-fiber group had greater reductions in glycated hemoglobin and body mass index and lower glycemic variability than the metformin group.”

    Human trialNewly diagnosed type 2 diabetes and overweight or obesity; compared with metformin monotherapy84 daysn = 48

    High-fiber diet altered gut microbiota, improved glycemic control, and reduced body weight in newly diagnosed type 2 diabetes and obesity

    Frontiers in microbiology

More on High-fiber diet

Health promotion model-based intervention

downin humans1

1 study
  1. Health promotion model-based intervention decreases glycated hemoglobin in humans.

    “Post-intervention assessments revealed declines in FPG and HbA1c levels in both groups, with the HPM group achieving significantly lower values than the conventional group (P<0.001).”

    Human trialone monthn = 142

    Hyperthyroidism complicated with diabetes mellitus using the health promotion model: changes in thyroid hormones, glucose-lipid metabolism, and inflammatory markers

    Journal of medical biochemistry

  2. Health promotion model-based intervention decreases glycated hemoglobin in patients with hyperthyroidism complicated by diabetes mellitus (P< 0.001).

    “significantly larger decreases in FPG, HbA1c, TC, and TG were identified in the HPM group (P< 0.001).”

    Human trialin patients with hyperthyroidism complicated by diabetes mellitusn = 142

    Hyperthyroidism complicated with diabetes mellitus using the health promotion model: changes in thyroid hormones, glucose-lipid metabolism, and inflammatory markers

    Journal of medical biochemistry

More on Health promotion model-based intervention

Multidisciplinary residential program

downin humans1

1 study
  1. Multidisciplinary residential program decreases glycated hemoglobin in humans.

    “In, regarding blood parameters, as there was a significant improvement in the overall values between pre and post recovery, it is noteworthy to mention how such intervention enhanced glycaemia (p < 0.05), glycosylated hemoglobin (p < 0.01), insulinemia (p < 0.05), total cholesterol (p < 0.001), LDL (p < 0.001), and triglyceride (p < 0.001) levels”

    Human trial8-weekn = 61

    The Effects of a Multidisciplinary Residential Program on the Risk Factors of Sarcopenic Obesity: An Open-Label Trial Study in a Cohort of Institutionalized Italian Adults with Obesity

    Nutrients

  2. Multidisciplinary residential program decreases glycated hemoglobin in humans (-0.81%, p < 0.05).

    “Glycemic control improved, with reductions in fasting glucose (-16.4 mg/dL), HbA1c (-0.81%), insulin (-2.77 mcU/mL), and HOMA-IR (-0.95; p < 0.05).”

    Human trial2-monthn = 61

    The Effects of a Multidisciplinary Residential Program on the Risk Factors of Sarcopenic Obesity: An Open-Label Trial Study in a Cohort of Institutionalized Italian Adults with Obesity

    Nutrients

More on Multidisciplinary residential program

Helicobacter pylori eradication-treatment regimen + metformin

downin humans1

1 study
  1. Helicobacter pylori eradication-treatment regimen + metformin decreases glycated hemoglobin in humans (Greater reduction of 1.76 percentage points versus eradication-treatment regimen alone (95% CI 1.43–2.09) and 1.77 percentage points versus metformin alone (95% CI 1.41–2.13)).

    “Assignment to the Helicobacter pylori eradication-treatment regimen combined with metformin was associated with greater short-term glycated hemoglobin improvement than assignment to either regimen alone.”

    Human trialType 2 diabetes mellitus and Helicobacter pylori infection; comparison with either regimen alone using archived summary data6 monthsn = 120

    Effects of a Helicobacter pylori -directed treatment regimen combined with metformin on glycemic control and metabolic and inflammatory status in type 2 diabetes mellitus

    The Journal of international medical research

More on Helicobacter pylori eradication-treatment regimen + metformin

All 64

Effects

12

Kidney failure

mediatesin humans1

1 study
  1. Glycated hemoglobin is linked with kidney failure in humans (Mediation of the relationship between body mass index and renal failure) (6.83% mediated).

    “five acted as mediators in the relationship between BMI and renal failure: cystatin C (12.34%), glucose (7.02%), glycated hemoglobin (HbA1c) (6.83%), diastolic blood pressure (6.37%)”

    HumansMediation of the relationship between body mass index and renal failure

    A Mendelian randomization analysis of the causal effect of body mass index on biomarkers and renal failure risk

    Medicine

More on Kidney failure

Lacunar stroke

mediatesin humans1

1 study
  1. Glycated hemoglobin is linked with lacunar stroke in humans (mediating WHRadjBMI effect on lacunar stroke) (23.0% (95% CI, -11.2% to 57.2%)).

    “glycated hemoglobin (23.0%; -11.2% to 57.2%)”

    Humansmediating WHRadjBMI effect on lacunar stroke

    Abdominal Adiposity and Lacunar Stroke: A Mendelian Randomization Mediation Study

    medRxivPreprint

More on Lacunar stroke

Muscle quality index

downin humans1

1 study
  1. Glycated hemoglobin is linked with lower muscle quality index in humans (initiating peritoneal dialysis) (β=-0.383, p<0.01).

    “HbA1c (β=-0.383; 95% CI: -0.132- to -0.033, R2=0.414)”

    Humansinitiating peritoneal dialysisn = 47

    Muscle Quality Index in Patients on Peritoneal Dialysis: Association with Clinical and Nutritional Factors

    Journal of nephrology

More on Muscle quality index

Handgrip strength

no changein humans1

1 study
  1. Glycated hemoglobin was not clearly linked with handgrip strength in humans (r=-0.16, p=0.14).

    “not in women (r=-0.16, p=0.14).”

    Humansfemalesn = 80

    Association Between Sex-specific Handgrip Strength and Plasma Glycated Hemoglobin Levels Among Older Adults: A Cross-sectional Study

    Canadian journal of diabetes

Frailty index

upin silico1

1 study
  1. Glycated hemoglobin increases frailty index in silico (β = 0.049, 95% CI: 0.031-0.067, p = 7.39 × 10−8).

    “glycated hemoglobin demonstrated significant associations with both the frailty index (β = 0.049, 95% confidence interval: 0.031-0.067, p = 7.39 × 10−8)”

    In silico

    Assessment of relationships between frailty and diabetes: A two-sample Mendelian randomization study

    The Journal of international medical research

More on Frailty index

Telomere length

mediatesin humans1

1 study
  1. Glycated hemoglobin is linked with telomere length in humans (mediating association of nickel with telomere length) (4.26%).

    “associations of nickel and metal mixture with telomere length were partially mediated by glycated hemoglobin, and the mediated proportions were 4.26% and 4.38%, respectively”

    Humansmediating association of nickel with telomere length

    Role of Glucose Metabolism in the Effects of Serum Metals on Telomere Length: Findings in Chinese Diabetic Population

    Biological trace element research

More on Telomere length

Major bleeding

no changein humans1

1 study
  1. Glycated hemoglobin was not clearly linked with major bleeding in humans (non-valvular atrial fibrillation).

    “No significant differences were observed in risks of major bleeding or other outcomes in this and other subgroups.”

    Humansnon-valvular atrial fibrillation2-yearn = 17,526

    Impact of glycated hemoglobin on 2-year clinical outcomes in elderly patients with atrial fibrillation: sub-analysis of ANAFIE Registry, a large observational study

    Cardiovascular diabetology

Tinnitus

no changein humans1

1 study
  1. Glycated hemoglobin was not clearly linked with tinnitus in humans (patients with diabetes).

    “No meaningful dependency was found between either patient's gender and tinnitus or the level of fasting blood sugar (FBS) and glycated hemoglobin (HbA1C).”

    Humanspatients with diabetesn = 250

    Diabetes Mellitus and Tinnitus: an Epidemiology Study

    Maedica

Frailty

no changein humans1

1 study
  1. Glycated hemoglobin was not clearly linked with frailty in humans.

    “In this study, HbA1c levels showed no significant association to frailty.”

    Humansn = 268

    Diabetes and frailty in the elderly. A prospective study of an outpatient population supported by general practitioners

    Revue medicale de Liege

AUC-C-peptide

downin humans1

1 study
  1. Glycated hemoglobin is linked with lower AUC-C-peptide in humans (readmitted non-sarcopenia patients).

    “Furthermore, as HbA1c and SDBG increased, AUC-C-peptide and AUC-insulin decreased in readmitted non-sarcopenia patients”

    Humansreadmitted non-sarcopenia patients

    Influence of glucose, insulin fluctuation, and glycosylated hemoglobin on the outcome of sarcopenia in patients with type 2 diabetes mellitus

    Journal of diabetes and its complications

More on AUC-C-peptide

All 12

Upstream

6

Frailty

upin silico1

1 study
  1. Frailty increases glycated hemoglobin in silico.

    “frailty was significantly associated with an increased risk of type 2 diabetes mellitus and higher levels of glycated hemoglobin, but not with type 1 diabetes mellitus.”

    In silico

    Assessment of relationships between frailty and diabetes: A two-sample Mendelian randomization study

    The Journal of international medical research

Early weight loss

no changein humans1

1 study
  1. Early weight loss showed no clear effect on glycated hemoglobin in humans (≥5% versus <5% early weight loss on tirzepatide).

    “Improvements in glycated hemoglobin were similar between subgroups”

    Human trial≥5% versus <5% early weight loss on tirzepatide52 weeksn = 893

    Association Between Early Weight Loss and Metabolic Outcomes with Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J Post Hoc Analysis

    Diabetes therapy : research, treatment and education of diabetes and related disorders

More on Early weight loss

Glucagon

no changein humans1

1 study
  1. Glucagon showed no clear effect on glycated hemoglobin in humans (metformin arm; across baseline glucagon subgroups).

    “while metformin showed consistent glucose-lowering effects across all glucagon subgroups”

    Human trialmetformin arm; across baseline glucagon subgroups1500 mg/day48 weeks

    Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study

    Diabetes research and clinical practice

More on Glucagon

Trimethylamine N-oxide

no changein humans1

1 study
  1. Trimethylamine N-oxide was not clearly linked with glycated hemoglobin in humans.

    “Serum TMAO was not associated with longitudinal changes in HbA1c, insulin or HOMA-IR.”

    Humansmedian follow-up of 8.9 yearsn = 2,088

    Serum trimethylamine-N-oxide is associated with incident type 2 diabetes in middle-aged and older adults: a prospective cohort study

    Journal of translational medicine

More on Trimethylamine N-oxide

Testosterone

downin humans1

1 study
  1. Testosterone decreases glycated hemoglobin in humans (testosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl) (-3.1 ± 9.2 vs. 3.2 ± 13.9%).

    “Men with T ≥ 264 ng/dl showed significant decreases in HbA1c at 12 months (-3.1 ± 9.2 vs. 3.2 ± 13.9%; p = 0.005)”

    Human trialtestosterone therapy in men with baseline T ≥ 264 ng/dl vs < 264 ng/dl12 monthsmales

    Baseline Testosterone Predicts Body Composition and Metabolic Response to Testosterone Therapy

    Frontiers in endocrinology

More on Testosterone

Idaho stock

downin mice1

1 study
  1. Idaho stock decreases glycated hemoglobin in mice.

    “although GHb levels were significantly lower in the Idaho mice.”

    Animals

    Hyperglycemia, impaired glucose tolerance and elevated glycated hemoglobin levels in a long-lived mouse stock

    Experimental gerontology

More on Idaho stock

Associations

55

Mild cognitive impairment

upin humans2mixedin humans1OR 1.9

3 studies
  1. Glycated hemoglobin is associated with mild cognitive impairment in humans (HbA1c ≥ 7%) (OR 1.90, 95% CI 1.00-3.60).

    “HbA1c ≥ 7% (1.90, 95% CI: 1.00, 3.60).”

    HumansHbA1c ≥ 7%

    Diabetes, prediabetes, and mild cognitive impairment among older adults: the Hitachi Health Study II

    Acta diabetologica

  2. Glycated hemoglobin predicts mild cognitive impairment in humans (patients with type 2 diabetes mellitus; multivariate models).

    “The multivariate models consistently identified age, education, disease duration, depression, and glycosylated hemoglobin level as independent predictors.”

    Reviewpatients with type 2 diabetes mellitus; multivariate models

    Risk Prediction Models for Mild Cognitive Impairment in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

    Diabetes, metabolic syndrome and obesity : targets and therapy

  3. Glycated hemoglobin predicts mild cognitive impairment in humans (mild cognitive impairment).

    “revealed the main predictors of MCI to be changes in glycated hemoglobin, brain-derived neurotrophic factor, and vascular endothelial growth factor-induced neovascularization.”

    Reviewmild cognitive impairmentn = 2,023

    Physical activity in mild cognitive impairment during aging and the description of its predictive factors: A systematic review

    Journal of bodywork and movement therapies

More on Mild cognitive impairment

Frontotemporal dementia

upin humans1mixedin humans1

2 studies
  1. Frontotemporal dementia is associated with glycated hemoglobin in humans (frontotemporal dementia patients compared with controls; GrimAge2 component-level analysis) (p < 0.05).

    “Component-level analyses showed increased smoking-related DNA methylation, systemic inflammation (tissue inhibitor of metalloproteinases 1, C-reactive protein), and glucose metabolism (glycated hemoglobin; all p < 0.05).”

    Humansfrontotemporal dementia patients compared with controls; GrimAge2 component-level analysisperipheral blood

    Frontotemporal dementia linked to faster aging on a DNA clock

    Annals of neurology

  2. Glycated hemoglobin is associated with frontotemporal dementia in humans (P non-linearity = 0.006).

    “HbA1c showed a U-shaped association with FTD”

    Humans

    Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Have Distinct Prediagnostic Blood Biochemical Profiles

    Annals of neurology

More on Frontotemporal dementia

Age

mixedin F. albicollis1upin humans1

2 studies
  1. Age is associated with glycated hemoglobin in humans (PMOS).

    “The 30s group had significantly higher total cholesterol and glycated hemoglobin levels than the <30 group”

    HumansPMOS

    A Generational Comparison of Physical and Laboratory Findings in Patients with Polyendocrine Metabolic Ovarian Syndrome in Japan

    Journal of clinical medicine

  2. Age is associated with glycated hemoglobin in F. albicollis (free-living population) (Decrease from age 1 to 5 years; increase thereafter).

    “Results show a strong decrease in glycated haemoglobin from age 1 to 5 years and an increase thereafter.”

    Animalsfree-living populationbloodn = 274

    Selective disappearance of individuals with high levels of glycated haemoglobin in a free-living bird

    Biology letters

Handgrip strength

downin humans2

2 studies
  1. Glycated hemoglobin is associated with handgrip strength in humans (r=-0.47, p=0.002).

    “A1C correlated inversely with HGS in men (r=-0.47, p=0.002)”

    Humansmalesn = 41

    Association Between Sex-specific Handgrip Strength and Plasma Glycated Hemoglobin Levels Among Older Adults: A Cross-sectional Study

    Canadian journal of diabetes

  2. Glycated hemoglobin is associated with handgrip strength in humans (hospitalized older adult inpatients).

    “low hemoglobin, and elevated HbA1C levels were independent risk factors for low HGS.”

    Humanshospitalized older adult inpatientsn = 135

    The clinical utility of handgrip strength as a malnutrition screening tool in hospitalized older adults: a cross-sectional study in Saudi Arabia

    Frontiers in medicine

Acetate

downin humans1

1 study
  1. Acetate is associated with glycated hemoglobin.

    “The results revealed that HbA1c was significantly negatively correlated with changes in acetate and total SCFAs.”

    Human trial84-day intervention

    High-fiber diet altered gut microbiota, improved glycemic control, and reduced body weight in newly diagnosed type 2 diabetes and obesity

    Frontiers in microbiology

  2. Acetate is associated with glycated hemoglobin in humans Within the high-fiber group; increased fecal acetate versus no increase (25 of 34 participants had increased fecal acetate).

    “Within the high-fiber group, participants with increased fecal acetate (25 of 34) had larger glycated hemoglobin reductions at Days 28 and 56”

    Human trialWithin the high-fiber group; increased fecal acetate versus no increaseDays 28 and 56n = 34

    High-fiber diet altered gut microbiota, improved glycemic control, and reduced body weight in newly diagnosed type 2 diabetes and obesity

    Frontiers in microbiology

More on Acetate

Skeletal muscle mass

downin humans1

1 study
  1. Glycated hemoglobin is associated with skeletal muscle mass in humans (r = −0.52).

    “The change in ASM / height2 (kg/m2) was also negatively correlated with the change in TAR (r = −0.37, P = 0.027) and HbA1c (r = −0.52, P = 0.001), but positively correlated with the change in TIR (r = 0.36, P = 0.036).”

    Human trial4 weeksn = 36

    Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

    Journal of diabetes investigation

  2. Glycated hemoglobin is associated with skeletal muscle mass in humans.

    “The change in ASM / weight (%) was negatively correlated with the change in glycated hemoglobin (%;P = 0.023).”

    Human trial4 weeksn = 36

    Changes in glycemic control and skeletal muscle mass indices after dapagliflozin treatment in individuals with type 1 diabetes mellitus

    Journal of diabetes investigation

Dementia

downin humans1upin humans1

1 study
  1. Glycated hemoglobin is linked with a lower risk of dementia in humans (type 2 diabetes, >50% of measurements vs <=50%) (aHR 0.79 (95% CI, 0.77-0.81)).

    “HbA1c 6% to <7%: aHR, 0.79 [95% CI, 0.77-0.81]”

    Humanstype 2 diabetes, >50% of measurements vs <=50%

    Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes

    JAMA neurology

  2. Glycated hemoglobin is linked with a higher risk of dementia in humans (type 2 diabetes, >50% of measurements vs <=50%) (aHR 1.74 (95% CI, 1.62-1.86)).

    “HbA1c≥10%: aHR, 1.74 [95% CI, 1.62-1.86]”

    Humanstype 2 diabetes, >50% of measurements vs <=50%

    Glycemic Control Over Multiple Decades and Dementia Risk in People With Type 2 Diabetes

    JAMA neurology

More on Dementia

Empagliflozin or dapagliflozin treatment

downin humans1

1 study
  1. Empagliflozin or dapagliflozin treatment is associated with glycated hemoglobin in humans (Type 2 diabetes mellitus and diabetic kidney disease; no non-SGLT2 inhibitor control group).

    “Over 12 months, glycated hemoglobin and fasting glucose levels decreased”

    HumansType 2 diabetes mellitus and diabetic kidney disease; no non-SGLT2 inhibitor control group12 monthsn = 452

    Longitudinal Changes in Renal, Glycemic, Metabolic, Hematological, and Inflammatory Parameters in Patients with Diabetic Kidney Disease Treated with Empagliflozin or Dapagliflozin: A 12-Month Real-World Cohort Study

    Preprints.orgPreprint

More on Empagliflozin or dapagliflozin treatment

Cardio–renal–metabolic integrated education

downin humans1

1 study
  1. Cardio–renal–metabolic integrated education is associated with glycated hemoglobin in humans (Adjusted difference −0.52%, 95% CI −0.70 to −0.34).

    “Glycaemic control improved (glycated haemoglobin change −0.71% vs −0.19%; adjusted difference −0.52%, 95% confidence interval −0.70 to −0.34; p<0.001).”

    HumansChronic heart failure, type 2 diabetes and chronic kidney disease stage 2–4; compared with usual education12 months

    Integrated education linked to fewer heart failure admissions

    ESC Congress 2026 abstract

More on Cardio–renal–metabolic integrated education

Serum tenascin C

downin humans1

1 study
  1. Serum tenascin C is associated with glycated hemoglobin in humans (Patients with prevalent cardiovascular risk factors; bivariate analyses).

    “TNC levels correlated negatively with age and glycated hemoglobin and positively with kidney function in bivariate analyses.”

    HumansPatients with prevalent cardiovascular risk factors; bivariate analysesn = 274

    Tenascin X and Tenascin C Serum Levels in Relation to Age and Cardiometabolic Risk Parameters

    International journal of molecular sciences

More on Serum tenascin C

Glucagon

downin humans1

1 study
  1. Glucagon predicts glycated hemoglobin in humans (acarbose arm; higher baseline glucagon tertile) (-1.32% high and -1.27% medium vs -0.87% low at 24 weeks; -1.23% high and -1.30% medium vs -0.79% low at 48 weeks).

    “In the acarbose group, higher baseline glucagon levels correlated with greater HbA1c reductions at 24 weeks”

    Human trialacarbose arm; higher baseline glucagon tertile300 mg/day24 and 48 weeks

    Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study

    Diabetes research and clinical practice

More on Glucagon

Frailty index increase

downin humans1

1 study
  1. Glycated hemoglobin is associated with frailty index increase in humans (baseline and average HbA1c levels over time, <7% versus ≥8%) (both P ≤ 0.002).

    “Baseline and average HbA1c levels over time of <7%, as compared with ≥8%, were associated with less increase in FI scores over 8 years (both P ≤ 0.002).”

    Human trialbaseline and average HbA1c levels over time, <7% versus ≥8%8 yearsn = 4,169

    An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) Trial

    Diabetes care

miR-152

downin humans1

1 study
  1. miR-152 is associated with glycated hemoglobin in adults with prediabetes (r=-0.37, P=.024).

    “The change in miR-152 positively correlated with the change in levels of the circulating metabolite 25-hydroxyvitamin D (r=0.33, P=.046) and negatively correlated with the change in glycated hemoglobin (r=-0.37, P=.024).”

    Human trialin adults with prediabetes

    Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control

    The Journal of nutritional biochemistry

More on miR-152

All 55

Funding

1 grant since 2023

Wellcome Trust£4.9M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Human trials show exercise lowers glycated hemoglobin after bariatric surgery, in type 2 diabetes with non-alcoholic fatty liver disease, and with whole-body high-intensity interval training in overweight or obesity. A review reports reductions with SGLT2 inhibitors in diabetic chronic kidney disease.

  2. Summary written from the findings.

Latest

Dec 2025: 25Jan 2026: 70Feb 2026: 88Mar 2026: 64Apr 2026: 20May 2026: 16Jun 2026: 29Jul 2026: 52Aug 2026: 57Sep 2026: 45Oct 2026: 90Nov 2026: 41597 papers in 12 months

See all 1,299 papers on glycated hemoglobin